NO20040093L - G-CSF konjugater - Google Patents
G-CSF konjugaterInfo
- Publication number
- NO20040093L NO20040093L NO20040093A NO20040093A NO20040093L NO 20040093 L NO20040093 L NO 20040093L NO 20040093 A NO20040093 A NO 20040093A NO 20040093 A NO20040093 A NO 20040093A NO 20040093 L NO20040093 L NO 20040093L
- Authority
- NO
- Norway
- Prior art keywords
- csf
- conjugates
- lysine residue
- polypeptide
- conjugated
- Prior art date
Links
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 title abstract 2
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 title abstract 2
- 101000746367 Homo sapiens Granulocyte colony-stimulating factor Proteins 0.000 abstract 2
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 abstract 2
- 229920001184 polypeptide Polymers 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 239000002202 Polyethylene glycol Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 125000003827 glycol group Chemical group 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 210000000265 leukocyte Anatomy 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 210000000440 neutrophil Anatomy 0.000 abstract 1
- 229920001223 polyethylene glycol Polymers 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 230000000638 stimulation Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/53—Colony-stimulating factor [CSF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/904,196 US6555660B2 (en) | 2000-01-10 | 2001-07-11 | G-CSF conjugates |
| DKPA200200447 | 2002-03-22 | ||
| DKPA200200708 | 2002-05-08 | ||
| PCT/DK2002/000482 WO2003006501A2 (en) | 2001-07-11 | 2002-07-10 | G-csf conjugates |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20040093L true NO20040093L (no) | 2004-03-09 |
Family
ID=27222576
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20040093A NO20040093L (no) | 2001-07-11 | 2004-01-09 | G-CSF konjugater |
Country Status (16)
| Country | Link |
|---|---|
| US (4) | US7550565B2 (no) |
| EP (1) | EP1425304B9 (no) |
| JP (1) | JP4444652B2 (no) |
| KR (1) | KR100961859B1 (no) |
| AT (1) | ATE468862T1 (no) |
| AU (1) | AU2002325819B2 (no) |
| BR (1) | BR0211071A (no) |
| CA (1) | CA2452582C (no) |
| DE (1) | DE60236522D1 (no) |
| HU (1) | HUP0400466A3 (no) |
| IL (1) | IL159524A0 (no) |
| MX (1) | MXPA04000231A (no) |
| NO (1) | NO20040093L (no) |
| NZ (1) | NZ530545A (no) |
| PL (1) | PL371781A1 (no) |
| WO (1) | WO2003006501A2 (no) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7173003B2 (en) | 2001-10-10 | 2007-02-06 | Neose Technologies, Inc. | Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF |
| US7214660B2 (en) | 2001-10-10 | 2007-05-08 | Neose Technologies, Inc. | Erythropoietin: remodeling and glycoconjugation of erythropoietin |
| PL1615945T3 (pl) | 2003-04-09 | 2012-03-30 | Ratiopharm Gmbh | Sposoby glikopegylacji i białka/peptydy wytwarzane tymi sposobami |
| US9005625B2 (en) | 2003-07-25 | 2015-04-14 | Novo Nordisk A/S | Antibody toxin conjugates |
| CN1867581B (zh) * | 2003-10-10 | 2012-02-01 | 诺沃挪第克公司 | Il-21衍生物 |
| US20060228331A1 (en) * | 2003-10-10 | 2006-10-12 | Novo Nordisk A/S | IL-21 Derivatives and variants |
| US7220407B2 (en) | 2003-10-27 | 2007-05-22 | Amgen Inc. | G-CSF therapy as an adjunct to reperfusion therapy in the treatment of acute myocardial infarction |
| US20080305992A1 (en) | 2003-11-24 | 2008-12-11 | Neose Technologies, Inc. | Glycopegylated erythropoietin |
| CN1897812B (zh) * | 2003-12-03 | 2011-08-17 | 生物种属学股份公司 | 糖聚乙二醇化的粒细胞集落刺激因子 |
| EP1586334A1 (en) * | 2004-04-15 | 2005-10-19 | TRASTEC scpa | G-CSF conjugates with peg |
| WO2006050247A2 (en) | 2004-10-29 | 2006-05-11 | Neose Technologies, Inc. | Remodeling and glycopegylation of fibroblast growth factor (fgf) |
| AU2005306894B2 (en) | 2004-11-05 | 2011-11-24 | Northwestern University | Use of SCF and G-CSF in the treatment of cerebral ischemia and neurological disorders |
| JP2006137678A (ja) * | 2004-11-10 | 2006-06-01 | Shionogi & Co Ltd | インターロイキン−２組成物 |
| US9029331B2 (en) | 2005-01-10 | 2015-05-12 | Novo Nordisk A/S | Glycopegylated granulocyte colony stimulating factor |
| WO2006121569A2 (en) | 2005-04-08 | 2006-11-16 | Neose Technologies, Inc. | Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants |
| KR20080027291A (ko) | 2005-06-01 | 2008-03-26 | 맥시겐 홀딩스 엘티디 | 피이지화된 지-씨에스에프 폴리펩타이드 및 그 제조방법 |
| KR100694994B1 (ko) | 2005-06-13 | 2007-03-14 | 씨제이 주식회사 | 사람 과립구 콜로니 형성인자 동종체 |
| US20070105755A1 (en) | 2005-10-26 | 2007-05-10 | Neose Technologies, Inc. | One pot desialylation and glycopegylation of therapeutic peptides |
| JP2009513627A (ja) * | 2005-10-27 | 2009-04-02 | ペプトロン カンパニー リミテッド | 生理活性物質−血液蛋白質複合体及びこれを利用する生理活性物質の安定化方法 |
| WO2007056191A2 (en) | 2005-11-03 | 2007-05-18 | Neose Technologies, Inc. | Nucleotide sugar purification using membranes |
| MY150687A (en) * | 2006-07-21 | 2014-02-28 | Femalon S P R L | Assay and kit for predicting implantation success in assisted fertilisation |
| US9176145B2 (en) | 2006-07-21 | 2015-11-03 | Femalon S.P.R.L. | Kit for predicting implantation success in assisted fertilization |
| EP2049144B8 (en) | 2006-07-21 | 2015-02-18 | ratiopharm GmbH | Glycosylation of peptides via o-linked glycosylation sequences |
| CN101573133B (zh) * | 2006-07-31 | 2014-08-27 | 诺沃-诺迪斯克有限公司 | Peg化延长的胰岛素 |
| ITMI20061624A1 (it) * | 2006-08-11 | 2008-02-12 | Bioker Srl | Mono-coniugati sito-specifici di g-csf |
| EP2054521A4 (en) | 2006-10-03 | 2012-12-19 | Novo Nordisk As | PROCESS FOR CLEANING POLYPEPTIDE CONJUGATES |
| HRP20130382T1 (hr) | 2007-04-03 | 2013-05-31 | Biogenerix Ag | Postupci lijeäśenja pomoä†u glikopegiliranog g-csf |
| CA2690611C (en) | 2007-06-12 | 2015-12-08 | Novo Nordisk A/S | Improved process for the production of nucleotide sugars |
| BRPI0905853B1 (pt) * | 2008-02-06 | 2019-03-26 | Biocon Limited | Processo para a produção de proteínas recombinantes, melhorando a incorporação de fosfato. |
| PL2257311T3 (pl) | 2008-02-27 | 2014-09-30 | Novo Nordisk As | Koniugaty cząsteczek czynnika VIII |
| US8034770B2 (en) | 2008-06-04 | 2011-10-11 | Amgen Inc. | FGF21 polypeptides comprising two or more mutations |
| BRPI0918553A2 (pt) * | 2008-09-19 | 2016-03-08 | Maxygen Inc | método para tratar ou previnir neutropenia em um paciente submetido à exposição à radiação, e, uso de uma variante de fator de estimulação de colônia de granulócito. |
| CA2739615C (en) | 2008-10-10 | 2017-12-05 | Amgen Inc. | Fgf21 mutants comprising polyethylene glycol and uses thereof |
| WO2010129600A2 (en) | 2009-05-05 | 2010-11-11 | Amgen Inc. | Fgf21 mutants and uses thereof |
| WO2010129503A1 (en) * | 2009-05-05 | 2010-11-11 | Amgen Inc. | Fgf21 mutants and uses thereof |
| MX2011013903A (es) * | 2009-06-17 | 2012-05-08 | Amgen Inc | Polipeptidos quimericos y usos de los mismos. |
| WO2011062862A1 (en) | 2009-11-17 | 2011-05-26 | Centocor Ortho Biotech Inc. | Improved bacterial membrane protein secrection |
| EP2679234A3 (en) | 2009-12-02 | 2014-04-23 | Amgen Inc. | Binding proteins that bind to human FGFR1C, human beta-klotho and both human FGFR1C and human beta-klotho |
| UA109888C2 (uk) * | 2009-12-07 | 2015-10-26 | ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ | |
| EP2542574B1 (en) | 2010-03-04 | 2017-08-09 | Pfenex Inc. | Method for producing soluble recombinant interferon protein without denaturing |
| AU2011235210B2 (en) | 2010-04-01 | 2015-07-16 | Pfenex Inc. | Methods for G-CSF production in a Pseudomonas host cell |
| CA2796055A1 (en) | 2010-04-15 | 2011-10-20 | Amgen Inc. | Human fgf receptor and .beta.-klotho binding proteins |
| US9320777B2 (en) | 2011-05-13 | 2016-04-26 | Bolder Biotechnology, Inc. | Methods and use of growth hormone supergene family protein analogs for treatment of radiation exposure |
| WO2016013725A1 (ko) * | 2014-07-23 | 2016-01-28 | 주식회사 이큐스앤자루 | 과립구 콜로니 자극인자 변이 단백질 또는 이의 트랜스페린 융합 단백질을 유효성분으로 포함하는 약학적 조성물 |
| KR101623906B1 (ko) | 2014-07-23 | 2016-05-24 | 주식회사 이큐스앤자루 | 과립구 콜로니 자극인자 변이 단백질 또는 이의 트랜스페린 융합 단백질을 유효성분으로 포함하는 약학적 조성물 |
| AU2015301936B2 (en) * | 2014-08-11 | 2019-03-07 | Delinia, Inc. | Modified IL-2 variants that selectively activate regulatory T cells for the treatment of autoimmune diseases |
| WO2016039163A1 (ja) | 2014-09-10 | 2016-03-17 | クリングルファーマ株式会社 | 神経疾患の治療に適したｈｇｆ製剤 |
| WO2016201448A2 (en) * | 2015-06-11 | 2016-12-15 | Prolong Pharmaceuticals, LLC | Pegylated granulocyte colony stimulating factor (gcsf) |
| US11229683B2 (en) | 2015-09-18 | 2022-01-25 | Bolder Biotechnology, Inc. | Hematopoietic growth factor proteins and analogs thereof and angiotensin converting enzyme inhibitors for treatment of radiation exposure |
| US20170204154A1 (en) | 2016-01-20 | 2017-07-20 | Delinia, Inc. | Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases |
| EP3538548A4 (en) | 2016-11-08 | 2020-08-19 | Delinia, Inc. | IL-2 VARIANTS FOR THE TREATMENT OF AUTOIMMUNE DISEASES |
Family Cites Families (102)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3209596C2 (de) * | 1982-03-17 | 1985-10-03 | Uni-Cardan Ag, 5200 Siegburg | Gleichlaufdrehgelenk |
| WO1985000817A1 (en) | 1983-08-10 | 1985-02-28 | Amgen | Microbial expression of interleukin ii |
| JPS61227526A (ja) | 1984-07-25 | 1986-10-09 | Chugai Pharmaceut Co Ltd | 新規なコロニー刺激因子 |
| ATE65798T1 (de) | 1985-02-08 | 1991-08-15 | Chugai Pharmaceutical Co Ltd | Menschlicher granuloxcyt-koloniestimulierungsfaktor. |
| US4810643A (en) | 1985-08-23 | 1989-03-07 | Kirin- Amgen Inc. | Production of pluripotent granulocyte colony-stimulating factor |
| US6004548A (en) * | 1985-08-23 | 1999-12-21 | Amgen, Inc. | Analogs of pluripotent granulocyte colony-stimulating factor |
| JPS63500636A (ja) | 1985-08-23 | 1988-03-10 | 麒麟麦酒株式会社 | 多分化能性顆粒球コロニー刺激因子をコードするｄｎａ |
| JPS6263335A (ja) | 1985-09-13 | 1987-03-20 | Fuji Photo Film Co Ltd | 化学反応情報の処理方法 |
| DE3681551D1 (de) | 1985-09-30 | 1991-10-24 | Chugai Pharmaceutical Co Ltd | Menschlicher granulozyten-colony stimulierender faktor. |
| EP0230980B2 (en) | 1986-01-22 | 1996-03-20 | Chugai Seiyaku Kabushiki Kaisha | Pharmaceutical agent for promoting the recovery of hemopoietic capacity |
| US4908773A (en) | 1987-04-06 | 1990-03-13 | Genex Corporation | Computer designed stabilized proteins and method for producing same |
| DK203187A (da) | 1986-04-22 | 1987-10-23 | Immunex Corp | Human g-csf proteinekspression |
| AU7675487A (en) | 1986-08-11 | 1988-05-19 | Cetus Corporation | Expression of granulocyte colony-stimulating factor |
| US4704692A (en) | 1986-09-02 | 1987-11-03 | Ladner Robert C | Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides |
| US5681720A (en) | 1986-12-23 | 1997-10-28 | Kyowa Hakko Co., Ltd. | DNA encoding human granulocyte colony stimulating factor plasmids and host cells comprising same, and methods of expressing the encoded polypeptide |
| NO176799C (no) | 1986-12-23 | 1995-05-31 | Kyowa Hakko Kogyo Kk | DNA som koder for et polypeptid, rekombinant plasmid som koder for og kan uttrykke et polypeptid og fremgangsmåte for fremstilling av dette polypeptid |
| US5362853A (en) * | 1986-12-23 | 1994-11-08 | Kyowa Hakko Kogyo Co., Ltd. | Polypeptide derivatives of human granulocyte colony stimulating factor |
| US5214132A (en) | 1986-12-23 | 1993-05-25 | Kyowa Hakko Kogyo Co., Ltd. | Polypeptide derivatives of human granulocyte colony stimulating factor |
| US4853871A (en) | 1987-04-06 | 1989-08-01 | Genex Corporation | Computer-based method for designing stablized proteins |
| US4904584A (en) | 1987-12-23 | 1990-02-27 | Genetics Institute, Inc. | Site-specific homogeneous modification of polypeptides |
| GB2213821B (en) | 1987-12-23 | 1992-01-02 | British Bio Technology | Synthetic human granulocyte colony stimulating factor gene |
| CA1340810C (en) | 1988-03-31 | 1999-11-02 | Motoo Yamasaki | Polypeptide derivatives of human granulocyte colony stimulating factor |
| KR0133561B1 (ko) | 1988-05-13 | 1998-04-21 | 스티븐 엠. 오드레 | 과립구 군체 자극인자의 정제방법 |
| EP0344796B1 (en) | 1988-06-03 | 1994-09-21 | Chugai Seiyaku Kabushiki Kaisha | Crystalline human granulocyte colony stimulating factor and process for preparing the same |
| US5025388A (en) | 1988-08-26 | 1991-06-18 | Cramer Richard D Iii | Comparative molecular field analysis (CoMFA) |
| US5218092A (en) | 1988-09-29 | 1993-06-08 | Kyowa Hakko Kogyo Co., Ltd. | Modified granulocyte-colony stimulating factor polypeptide with added carbohydrate chains |
| US5349052A (en) * | 1988-10-20 | 1994-09-20 | Royal Free Hospital School Of Medicine | Process for fractionating polyethylene glycol (PEG)-protein adducts and an adduct for PEG and granulocyte-macrophage colony stimulating factor |
| US5104651A (en) | 1988-12-16 | 1992-04-14 | Amgen Inc. | Stabilized hydrophobic protein formulations of g-csf |
| US6166183A (en) | 1992-11-30 | 2000-12-26 | Kirin-Amgen, Inc. | Chemically-modified G-CSF |
| US20020177688A1 (en) | 1988-12-22 | 2002-11-28 | Kirin-Amgen, Inc., | Chemically-modified G-CSF |
| WO1990006952A1 (fr) | 1988-12-22 | 1990-06-28 | Kirin-Amgen, Inc. | Facteur de stimulation de colonies de granulocytes modifies chimiquement |
| US5122614A (en) | 1989-04-19 | 1992-06-16 | Enzon, Inc. | Active carbonates of polyalkylene oxides for modification of polypeptides |
| US5166322A (en) | 1989-04-21 | 1992-11-24 | Genetics Institute | Cysteine added variants of interleukin-3 and chemical modifications thereof |
| US5109119A (en) | 1989-06-06 | 1992-04-28 | Schering Corporation | Crystalline r-h-gm-csf and method |
| IE66494B1 (en) | 1989-09-26 | 1996-01-10 | Immunex Corp | Granulocyte-colony stimulating factor receptors |
| AU641949B2 (en) | 1989-10-10 | 1993-10-07 | Amgen, Inc. | Compositions and methods for treating or preventing infections in canine and feline animals |
| US5265030A (en) | 1990-04-24 | 1993-11-23 | Scripps Clinic And Research Foundation | System and method for determining three-dimensional structures of proteins |
| GB9107846D0 (en) | 1990-04-30 | 1991-05-29 | Ici Plc | Polypeptides |
| US5399345A (en) * | 1990-05-08 | 1995-03-21 | Boehringer Mannheim, Gmbh | Muteins of the granulocyte colony stimulating factor |
| DE4014750A1 (de) | 1990-05-08 | 1991-11-14 | Boehringer Mannheim Gmbh | Muteine des granulozyten-stimulierenden faktors (g-csf) |
| JP3249147B2 (ja) | 1990-06-01 | 2002-01-21 | キリン−アムジエン・インコーポレーテツド | 生理活性蛋白含有経口製剤 |
| IE912365A1 (en) | 1990-07-23 | 1992-01-29 | Zeneca Ltd | Continuous release pharmaceutical compositions |
| DE69129697T3 (de) | 1990-08-29 | 2004-01-29 | Inst Genetics Llc | Aus mehreren domänen bestehende hämatopoese-stimulatoren |
| US5124297A (en) | 1990-12-07 | 1992-06-23 | Amoco Corporation | Olefin polymerization and copolymerization catalyst |
| DE4105480A1 (de) | 1991-02-21 | 1992-08-27 | Boehringer Mannheim Gmbh | Verbesserte aktivierung von rekombinanten proteinen |
| GB2253852B (en) | 1991-02-26 | 1995-03-22 | Ici Plc | Vector for expression of heterologous polypeptide comprising inducible selection system |
| US6565841B1 (en) | 1991-03-15 | 2003-05-20 | Amgen, Inc. | Pulmonary administration of granulocyte colony stimulating factor |
| US5157736A (en) * | 1991-04-19 | 1992-10-20 | International Business Machines Corporation | Apparatus and method for optical recognition of chemical graphics |
| JP3417558B2 (ja) | 1991-05-10 | 2003-06-16 | ジェネンテク，インコーポレイテッド | 配位子作用薬および拮抗薬の選択 |
| WO1993001484A1 (en) | 1991-07-11 | 1993-01-21 | The Regents Of The University Of California | A method to identify protein sequences that fold into a known three-dimensional structure |
| US5386507A (en) | 1991-07-18 | 1995-01-31 | Teig; Steven L. | Computer graphics system for selectively modelling molecules and investigating the chemical and physical properties thereof |
| US5281698A (en) | 1991-07-23 | 1994-01-25 | Cetus Oncology Corporation | Preparation of an activated polymer ester for protein conjugation |
| AU666866B2 (en) | 1991-08-30 | 1996-02-29 | Fred Hutchinson Cancer Research Center | Hybrid cytokines |
| JP2638359B2 (ja) | 1991-11-26 | 1997-08-06 | 富士通株式会社 | 分子動力学法の拘束条件作成装置 |
| EP0668914B1 (en) | 1992-06-09 | 2000-08-16 | Chiron Corporation | Crystallization of m-csf |
| ZA933926B (en) | 1992-06-17 | 1994-01-03 | Amgen Inc | Polyoxymethylene-oxyethylene copolymers in conjuction with blomolecules |
| US6153183A (en) | 1992-11-24 | 2000-11-28 | G. D. Searle & Company | Co-administration of interleukin-3 mutant polypeptides with CSF's or cytokines for multi-lineage hematopoietic cell production |
| US5772992A (en) | 1992-11-24 | 1998-06-30 | G.D. Searle & Co. | Compositions for co-administration of interleukin-3 mutants and other cytokines and hematopoietic factors |
| EP1361273A3 (en) | 1992-11-24 | 2004-02-11 | G.D. Searle & Co. | Interleukin-3 (IL-3) multiple mutation polypeptides |
| US5738849A (en) | 1992-11-24 | 1998-04-14 | G. D. Searle & Co. | Interleukin-3 (IL-3) variant fusion proteins, their recombinant production, and therapeutic compositions comprising them |
| US6057133A (en) | 1992-11-24 | 2000-05-02 | G. D. Searle | Multivariant human IL-3 fusion proteins and their recombinant production |
| US5424963A (en) * | 1992-11-25 | 1995-06-13 | Photon Research Associates, Inc. | Molecular dynamics simulation method and apparatus |
| US5581476A (en) * | 1993-01-28 | 1996-12-03 | Amgen Inc. | Computer-based methods and articles of manufacture for preparing G-CSF analogs |
| JP2720140B2 (ja) * | 1993-02-03 | 1998-02-25 | 日東化学工業株式会社 | フェニル基を有する光学活性α−ヒドロキシカルボン酸の製造法 |
| DE69521880T2 (de) | 1994-02-08 | 2002-01-03 | Amgen Inc., Thousand Oaks | Orales verabreichungssystem von chemischmodifizierten proteinen g-csf |
| JP4011106B2 (ja) | 1994-02-23 | 2007-11-21 | 協和醗酵工業株式会社 | 血小板増殖促進剤 |
| US5635599A (en) | 1994-04-08 | 1997-06-03 | The United States Of America As Represented By The Department Of Health And Human Services | Fusion proteins comprising circularly permuted ligands |
| US5576941A (en) * | 1994-08-10 | 1996-11-19 | York Technologies, Inc. | Modular power supply system |
| US5824784A (en) | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
| AU4658596A (en) | 1995-02-03 | 1996-08-21 | G.D. Searle & Co. | Novel c-mpl ligands |
| US6017523A (en) | 1995-06-06 | 2000-01-25 | G.D. Searle & Co. | Therapeutic methods employing mutant human interleukin-3 (IL-3) polypeptides |
| SE9503380D0 (sv) | 1995-09-29 | 1995-09-29 | Pharmacia Ab | Protein derivatives |
| EP0870027A1 (en) | 1995-10-05 | 1998-10-14 | G.D. Searle & Co. | Novel c-mpl receptor agonists |
| US6066318A (en) * | 1995-10-05 | 2000-05-23 | G.D. Searle & Co. | Multi-functional hematopoietic fusion proteins between sequence rearranged C-MPL receptor agonists and other hematopoietic factors |
| IL123832A0 (en) | 1995-10-05 | 1998-10-30 | Searle & Co | Multi-functional hematopoietic receptor antagonists |
| US6100070A (en) * | 1995-10-05 | 2000-08-08 | G. D. Searle & Co. | G-CSF receptor agonists |
| WO1997012977A1 (en) | 1995-10-05 | 1997-04-10 | G.D. Searle & Co. | Novel g-csf receptor agonists |
| US5969105A (en) | 1996-10-25 | 1999-10-19 | Feng; Yiqing | Stem cell factor receptor agonists |
| US6660257B1 (en) | 1996-10-25 | 2003-12-09 | Pharmacia Corporation | Circular permuteins of flt3 ligand |
| PL333023A1 (en) | 1996-10-25 | 1999-11-08 | Searle & Co | Chimerical antagonists of haeomogenic multifunctional receptors |
| AU751498B2 (en) | 1997-04-11 | 2002-08-15 | G.D. Searle & Co. | flt3 ligand chimeric proteins |
| KR100241257B1 (ko) | 1997-05-22 | 2000-02-01 | 한승수 | 인체 과립구 콜로니 자극 인자 활성물질 및 그것의 제조방법 |
| JP4011124B2 (ja) | 1997-06-06 | 2007-11-21 | 協和醗酵工業株式会社 | 化学修飾ポリペプチド |
| ES2297889T3 (es) | 1997-07-14 | 2008-05-01 | Bolder Biotechnology, Inc. | Derivados de hormona de crecimiento y proteinas relacionadas. |
| US5985263A (en) | 1997-12-19 | 1999-11-16 | Enzon, Inc. | Substantially pure histidine-linked protein polymer conjugates |
| EE05214B1 (et) | 1998-04-28 | 2009-10-15 | Applied Research Systems ARS Holding N.V. | Polool-IFN- β konjugaat, selle valmistamismeetod ja farmatseutiline kompositsioon |
| US6451986B1 (en) * | 1998-06-22 | 2002-09-17 | Immunex Corporation | Site specific protein modification |
| EP1115854A1 (en) | 1998-09-25 | 2001-07-18 | G.D. Searle & Co. | Method of producing permuteins by scanning permutagenesis |
| US6420339B1 (en) | 1998-10-14 | 2002-07-16 | Amgen Inc. | Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility |
| AU770131B2 (en) | 1999-01-06 | 2004-02-12 | Xencor, Inc. | Nucleic acids and proteins corresponding to mutants of G-CSF with granulopoietic activity |
| IL144361A0 (en) | 1999-01-29 | 2002-05-23 | Hoffmann La Roche | Gcsf conjugates |
| JP2000319298A (ja) | 1999-03-04 | 2000-11-21 | Seibutsu Bunshi Kogaku Kenkyusho:Kk | 蛋白質複合体の結晶、構造座標、及び構造座標の使用 |
| KR100356140B1 (ko) | 1999-07-08 | 2002-10-19 | 한미약품공업 주식회사 | 인간 과립구 콜로니 자극인자 변이체 및 이의 생산 방법 |
| KR100773323B1 (ko) * | 2000-01-10 | 2007-11-05 | 맥시겐 홀딩스 리미티드 | 지-씨에스에프 접합체 |
| US6831158B2 (en) * | 2000-01-10 | 2004-12-14 | Maxygen Holdings Ltd. | G-CSF conjugates |
| US6555660B2 (en) * | 2000-01-10 | 2003-04-29 | Maxygen Holdings Ltd. | G-CSF conjugates |
| US6646110B2 (en) * | 2000-01-10 | 2003-11-11 | Maxygen Holdings Ltd. | G-CSF polypeptides and conjugates |
| EP1354045A2 (en) | 2000-09-07 | 2003-10-22 | Eli Lilly And Company | Hyperglycosylated polypeptides |
| MXPA03002045A (es) | 2000-09-08 | 2003-07-24 | Amgen Inc | Composiciones analogas de factor estimulador de colonias de granulocitos y metodos para su elaboracion. |
| GB0022877D0 (en) | 2000-09-18 | 2000-11-01 | Isis Innovation | Analogues |
| WO2002036626A1 (en) * | 2000-11-02 | 2002-05-10 | Maxygen Aps | Single-chain multimeric polypeptides |
| US20020142964A1 (en) | 2000-11-02 | 2002-10-03 | Nissen Torben Lauesgaard | Single-chain polypeptides |
-
2002
- 2002-07-10 EP EP02760160A patent/EP1425304B9/en not_active Revoked
- 2002-07-10 NZ NZ530545A patent/NZ530545A/en not_active IP Right Cessation
- 2002-07-10 JP JP2003512271A patent/JP4444652B2/ja not_active Expired - Fee Related
- 2002-07-10 DE DE60236522T patent/DE60236522D1/de not_active Expired - Lifetime
- 2002-07-10 MX MXPA04000231A patent/MXPA04000231A/es active IP Right Grant
- 2002-07-10 AU AU2002325819A patent/AU2002325819B2/en not_active Ceased
- 2002-07-10 KR KR1020047000431A patent/KR100961859B1/ko not_active Expired - Fee Related
- 2002-07-10 HU HU0400466A patent/HUP0400466A3/hu active IP Right Revival
- 2002-07-10 CA CA2452582A patent/CA2452582C/en not_active Expired - Fee Related
- 2002-07-10 IL IL15952402A patent/IL159524A0/xx unknown
- 2002-07-10 WO PCT/DK2002/000482 patent/WO2003006501A2/en not_active Ceased
- 2002-07-10 BR BR0211071-7A patent/BR0211071A/pt not_active Application Discontinuation
- 2002-07-10 AT AT02760160T patent/ATE468862T1/de not_active IP Right Cessation
- 2002-07-10 PL PL02371781A patent/PL371781A1/xx not_active Application Discontinuation
-
2004
- 2004-01-09 NO NO20040093A patent/NO20040093L/no not_active Application Discontinuation
-
2006
- 2006-08-10 US US11/463,861 patent/US7550565B2/en not_active Expired - Fee Related
- 2006-08-10 US US11/463,867 patent/US7696153B2/en not_active Expired - Fee Related
- 2006-08-10 US US11/463,863 patent/US7550566B2/en not_active Expired - Fee Related
-
2010
- 2010-02-18 US US12/707,831 patent/US20110020266A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP4444652B2 (ja) | 2010-03-31 |
| WO2003006501A2 (en) | 2003-01-23 |
| KR100961859B1 (ko) | 2010-06-09 |
| HUP0400466A3 (en) | 2006-01-30 |
| MXPA04000231A (es) | 2004-05-04 |
| CA2452582C (en) | 2013-01-22 |
| US20060286068A1 (en) | 2006-12-21 |
| CA2452582A1 (en) | 2003-01-23 |
| US7550566B2 (en) | 2009-06-23 |
| JP2005506317A (ja) | 2005-03-03 |
| US20070010660A1 (en) | 2007-01-11 |
| WO2003006501A3 (en) | 2004-03-25 |
| EP1425304B9 (en) | 2010-09-08 |
| EP1425304B1 (en) | 2010-05-26 |
| US7550565B2 (en) | 2009-06-23 |
| US20110020266A1 (en) | 2011-01-27 |
| AU2002325819B2 (en) | 2008-06-19 |
| NZ530545A (en) | 2006-10-27 |
| DE60236522D1 (de) | 2010-07-08 |
| BR0211071A (pt) | 2004-12-21 |
| US7696153B2 (en) | 2010-04-13 |
| PL371781A1 (en) | 2005-06-27 |
| EP1425304A2 (en) | 2004-06-09 |
| IL159524A0 (en) | 2004-06-01 |
| US20060286069A1 (en) | 2006-12-21 |
| KR20040084884A (ko) | 2004-10-06 |
| HUP0400466A2 (hu) | 2005-01-28 |
| ATE468862T1 (de) | 2010-06-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE468862T1 (de) | G-csf konjugate | |
| DK1180121T3 (da) | Langtidsvirkende insulinotrope peptider | |
| LTC2599503I2 (lt) | Interferono beta-1A polimero konjugatai ir jų panaudojimas | |
| BE2013C033I2 (no) | ||
| BR9910251A (pt) | Estimulação hematopoiética | |
| ES2149774T3 (es) | Aportacion dirigida de genes que codifican proteinas secretoras. | |
| MXPA04005266A (es) | Inmunocitocinas con selectividad modulada. | |
| ITMI20061624A1 (it) | Mono-coniugati sito-specifici di g-csf | |
| EP0643772A1 (en) | VARIANTS OF TISSUE PLASMINOGEN ACTIVATOR WITH IMPROVED THERAPEUTIC EFFECT. | |
| IL196908A0 (en) | Glycoprotein synthesis | |
| SG149685A1 (en) | Polymer conjugates of neublastin and methods of using same | |
| IL126152A0 (en) | Recombinant adenoviral vectors for human tumor gene therapy | |
| WO2003074547A3 (en) | Biologically active complex comprising alpha-lcatalbumin or a variant thereof, and a cofactor | |
| CA2373252A1 (en) | Long lasting anti-angiogenic peptides | |
| IL130526A0 (en) | Novel anti-allergenic agents | |
| ECSP972139A (es) | Conjugados de interferon (caso ran 410077) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |